Acetazolamide
Acetazolamide is the medication that causes hypokalemia, metabolic acidosis (low bicarbonate), and glycosuria. This carbonic anhydrase inhibitor acts on the proximal tubule to inhibit bicarbonate reabsorption, leading to urinary bicarbonate loss and subsequent metabolic acidosis, while also causing potassium wasting and glycosuria as part of a proximal renal tubular acidosis (Fanconi-like) syndrome 1, 2, 3.
Mechanism of Action and Clinical Effects
Acetazolamide inhibits carbonic anhydrase in the proximal tubule, which blocks bicarbonate reabsorption. This creates a characteristic triad:
- Metabolic acidosis: Direct loss of bicarbonate in urine, with normal anion gap 2, 3
- Hypokalemia: Enhanced distal sodium delivery increases potassium secretion 1
- Glycosuria: Impaired proximal tubular glucose reabsorption as part of generalized proximal tubular dysfunction 2
Clinical Context and Guidelines
Acetazolamide is specifically mentioned in KDIGO 2021 guidelines as an adjunctive diuretic for resistant edema in nephrotic syndrome, though it is noted as a weak diuretic that may help treat metabolic alkalosis 4. The guidelines explicitly warn to monitor for hypokalemia and acidosis as adverse effects 4.
Recent evidence from heart failure management shows acetazolamide can improve diuresis when added to loop diuretics, though this comes at the cost of acid-base disturbances 5, 6.
Important Clinical Distinctions
Do not confuse with other diuretics:
- Loop and thiazide diuretics cause hypokalemia but produce metabolic alkalosis (not acidosis) and do not cause glycosuria 7, 4, 8, 9, 10
- NSAIDs can rarely cause renal tubular acidosis with hypokalemia but through a different mechanism (distal RTA) and are not typically associated with glycosuria 11, 12
Monitoring Requirements
When acetazolamide is prescribed, monitor:
- Serum electrolytes (particularly potassium) every 5-7 days initially 1
- Arterial blood gases or serum bicarbonate to assess acidosis severity
- Urine glucose if concerned about proximal tubular dysfunction
- Consider discontinuation if severe hypokalemia (K+ <3.5 mmol/L) or symptomatic acidosis develops 1, 2
Management of Adverse Effects
If hypokalemia and acidosis develop:
- Potassium chloride supplementation addresses both issues simultaneously (replaces potassium and provides chloride to help correct acidosis)
- Reduce or discontinue acetazolamide
- Consider alternative diuretic strategies 4
The combination of these three findings—hypokalemia, low bicarbonate (metabolic acidosis), and glycosuria—is pathognomonic for proximal tubular dysfunction, most commonly medication-induced by carbonic anhydrase inhibitors like acetazolamide 2, 3, 13.